165 related articles for article (PubMed ID: 34889277)
1. Successful treatment with denosumab for pelvic fibrous dysplasia: A case report and review of the literature.
Ikuta K; Sakai T; Koike H; Ito K; Imagama S; Nishida Y
Medicine (Baltimore); 2021 Dec; 100(49):e28138. PubMed ID: 34889277
[TBL] [Abstract][Full Text] [Related]
2. Denosumab Reduces Lesional Fluoride Skeletal Burden on Na[18F]F PET-CT in Patients With Fibrous Dysplasia/McCune-Albright Syndrome.
van der Bruggen W; Vriens D; Meier ME; Smit F; Winter EM; de Geus-Oei LF; Appelman-Dijkstra NM
J Clin Endocrinol Metab; 2021 Jul; 106(8):e2980-e2994. PubMed ID: 33788944
[TBL] [Abstract][Full Text] [Related]
3. Denosumab for craniofacial fibrous dysplasia: duration of efficacy and post-treatment effects.
Raborn LN; Burke AB; Ebb DH; Collins MT; Kaban LB; Boyce AM
Osteoporos Int; 2021 Sep; 32(9):1889-1893. PubMed ID: 33772327
[TBL] [Abstract][Full Text] [Related]
4. Clinical value of RANKL, OPG, IL-6 and sclerostin as biomarkers for fibrous dysplasia/McCune-Albright syndrome.
Meier ME; Hagelstein-Rotman M; Streefland TCM; Winter EM; Bravenboer N; Appelman-Dijkstra NM
Bone; 2023 Jun; 171():116744. PubMed ID: 36958543
[TBL] [Abstract][Full Text] [Related]
5. Denosumab Use in Adults With Fibrous Dysplasia: Case Reports and Review of the Literature.
Hung C; Shibli-Rahhal A
Endocr Pract; 2022 Nov; 28(11):1196-1201. PubMed ID: 35952985
[TBL] [Abstract][Full Text] [Related]
6. Denosumab Treatment for Giant Cell Tumors, Aneurysmal Bone Cysts, and Fibrous Dysplasia-Risks and Benefits.
Pan KS; Boyce AM
Curr Osteoporos Rep; 2021 Apr; 19(2):141-150. PubMed ID: 33616817
[TBL] [Abstract][Full Text] [Related]
7. Safety of therapy with and withdrawal from denosumab in fibrous dysplasia and McCune-Albright syndrome: an observational study.
Meier ME; Clerkx SN; Winter EM; Pereira AM; van de Ven AC; van de Sande MAJ; Appelman-Dijkstra NM
J Bone Miner Res; 2021 Sep; 36(9):1729-1738. PubMed ID: 34076303
[TBL] [Abstract][Full Text] [Related]
8. Rapid biochemical response to denosumab in fibrous dysplasia of bone: report of two cases.
Ganda K; Seibel MJ
Osteoporos Int; 2014 Feb; 25(2):777-82. PubMed ID: 24311113
[TBL] [Abstract][Full Text] [Related]
9. Denosumab use in bone fibrous dysplasia refractory to bisphosphonate: A retrospective multicentric study.
Trojani MC; Gensburger D; Bagouet F; Cortet B; Couture G; Marcelli C; Mehsen Cetre N; Breuil V; Chapurlat R
Bone; 2023 Sep; 174():116819. PubMed ID: 37301527
[TBL] [Abstract][Full Text] [Related]
10. Treatment of fibrous dysplasia: focus on denosumab.
Huzum B; Antoniu S; Dragomir R
Expert Opin Biol Ther; 2022 Mar; 22(3):397-405. PubMed ID: 34964677
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of antiresorptive agents in fibrous dysplasia and McCune Albright syndrome, a systematic review and meta-analysis.
Bertin H; Moussa MS; Komarova S
Rev Endocr Metab Disord; 2023 Dec; 24(6):1103-1119. PubMed ID: 37632645
[TBL] [Abstract][Full Text] [Related]
12. Early evaluation of the therapeutic effect of denosumab on tartrate-resistant acid phosphatase 5b expression in a giant cell tumor of bone: a case report.
Watanabe N; Matsumoto S; Shimoji T; Ae K; Tanizawa T; Gokita T; Motoi N; Ueno T; Koizumi M
BMC Res Notes; 2014 Sep; 7():608. PubMed ID: 25193435
[TBL] [Abstract][Full Text] [Related]
13. Clinical and translational pharmacological aspects of the management of fibrous dysplasia of bone.
Rotman M; Hamdy NAT; Appelman-Dijkstra NM
Br J Clin Pharmacol; 2019 Jun; 85(6):1169-1179. PubMed ID: 30471134
[TBL] [Abstract][Full Text] [Related]
14. Denosumab in Patients With Fibrous Dysplasia Previously Treated With Bisphosphonates.
Majoor BCJ; Papapoulos SE; Dijkstra PDS; Fiocco M; Hamdy NAT; Appelman-Dijkstra NM
J Clin Endocrinol Metab; 2019 Dec; 104(12):6069-6078. PubMed ID: 31390018
[TBL] [Abstract][Full Text] [Related]
15. Bisphosphonate treatment in craniofacial fibrous dysplasia--a case report and review of the literature.
Mäkitie AA; Törnwall J; Mäkitie O
Clin Rheumatol; 2008 Jun; 27(6):809-12. PubMed ID: 18247080
[TBL] [Abstract][Full Text] [Related]
16. Denosumab treatment for fibrous dysplasia.
Boyce AM; Chong WH; Yao J; Gafni RI; Kelly MH; Chamberlain CE; Bassim C; Cherman N; Ellsworth M; Kasa-Vubu JZ; Farley FA; Molinolo AA; Bhattacharyya N; Collins MT
J Bone Miner Res; 2012 Jul; 27(7):1462-70. PubMed ID: 22431375
[TBL] [Abstract][Full Text] [Related]
17. Elevated levels of circulating fibroblast growth factor 23 with hypercalcemia following discontinuation of denosumab.
Uchida T; Yamaguchi H; Kushima C; Yonekawa T; Nakazato M
Endocr J; 2020 Jan; 67(1):31-35. PubMed ID: 31527321
[TBL] [Abstract][Full Text] [Related]
18. Different patterns of change in bone turnover markers during treatment with bone-modifying agents for breast cancer patients with bone metastases.
Nishimukai A; Higuchi T; Ozawa H; Yanai A; Miyagawa Y; Murase K; Imamura M; Takatsuka Y; Miyoshi Y
Breast Cancer; 2017 Mar; 24(2):245-253. PubMed ID: 27040403
[TBL] [Abstract][Full Text] [Related]
19. Safety and Efficacy of Denosumab for Fibrous Dysplasia of Bone.
de Castro LF; Michel Z; Pan K; Taylor J; Szymczuk V; Paravastu S; Saboury B; Papadakis GZ; Li X; Milligan K; Boyce B; Paul SM; Collins MT; Boyce AM
N Engl J Med; 2023 Feb; 388(8):766-768. PubMed ID: 36812441
[No Abstract] [Full Text] [Related]
20. Bisphosphonate therapy for fibrous dysplasia.
DiMeglio LA
Pediatr Endocrinol Rev; 2007 Aug; 4 Suppl 4():440-5. PubMed ID: 17982393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
